| Crohn Disease
Avsola vs Cyltezo
Side-by-side clinical, coverage, and cost comparison for crohn disease.Deep comparison between: Avsola vs Cyltezo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsCyltezo has a higher rate of injection site reactions vs Avsola based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Cyltezo but not Avsola, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Avsola
Cyltezo
At A Glance
IV infusion
Every 6-8 weeks
TNF-alpha inhibitor
SC injection
Every other week
TNF-alpha inhibitor
Indications
- Crohn Disease
- Ulcerative Colitis
- Rheumatoid Arthritis
- Arthritis, Psoriatic
- Psoriasis
- Rheumatoid Arthritis
- Arthritis, Psoriatic
- Ankylosing spondylitis
- Crohn Disease
- Ulcerative Colitis
- Psoriasis vulgaris
- Panuveitis
Dosing
Crohn Disease, Ulcerative Colitis, Arthritis, Psoriatic, Psoriasis 5 mg/kg IV induction at weeks 0, 2, and 6, followed by 5 mg/kg every 8 weeks maintenance.
Rheumatoid Arthritis 3 mg/kg IV induction at weeks 0, 2, and 6, followed by 3 mg/kg every 8 weeks maintenance, in combination with methotrexate.
Ankylosing Spondylitis 5 mg/kg IV induction at weeks 0, 2, and 6, followed by 5 mg/kg every 6 weeks maintenance.
Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis 40 mg every other week SC; some RA patients not receiving MTX may benefit from 40 mg every week or 80 mg every other week.
Crohn Disease, Ulcerative Colitis 160 mg on Day 1, 80 mg on Day 15, then 40 mg every other week SC starting Day 29.
Psoriasis vulgaris, Panuveitis 80 mg initial dose, then 40 mg every other week SC starting 1 week after initial dose.
Contraindications
- Doses >5 mg/kg in patients with moderate or severe heart failure
- Previous severe hypersensitivity reaction to infliximab products, any inactive ingredient of AVSOLA, or murine proteins
—
Adverse Reactions
Most common (>10%) Infections (upper respiratory, sinusitis, pharyngitis), infusion-related reactions, headache, abdominal pain
Serious Pneumonia, cellulitis, abscess, skin ulceration, sepsis, bacterial infection, lymphoma, hepatotoxicity
Postmarketing Neutropenia, agranulocytosis, interstitial lung disease, Stevens-Johnson Syndrome, toxic epidermal necrolysis, acute liver failure, anaphylactic shock, cerebrovascular accidents, myocardial ischemia
Most common (>=5%) Injection site reactions, upper respiratory infection, headache, rash, sinusitis, accidental injury, nausea, urinary tract infection, flu syndrome, abdominal pain, hyperlipidemia, back pain, hypertension, hematuria
Serious Serious infections (pneumonia, septic arthritis, cellulitis, diverticulitis, pyelonephritis), malignancies, acute liver failure, hepatitis B reactivation, neurologic reactions, hematological reactions, heart failure, autoimmunity
Postmarketing Diverticulitis, large bowel perforations, pancreatitis, liver failure, autoimmune hepatitis, sarcoidosis, Merkel Cell Carcinoma, demyelinating disorders, cerebrovascular accident, interstitial lung disease, pulmonary embolism, Stevens Johnson Syndrome, cutaneous vasculitis, erythema multiforme, new or worsening psoriasis, alopecia, systemic vasculitis, deep vein thrombosis
Pharmacology
TNF-alpha inhibitor; chimeric IgG1kappa monoclonal antibody that neutralizes TNFalpha by binding with high affinity to the soluble and transmembrane forms of TNFalpha, inhibiting binding of TNFalpha with its receptors.
Adalimumab-adbm is a TNF-alpha antagonist that binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors, modulating inflammatory responses and reducing concentrations of acute phase reactants such as CRP and ESR.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Avsola
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
Cyltezo
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Avsola
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Cyltezo
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Avsola
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Cyltezo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Avsola.
No savings programs available for Cyltezo.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AvsolaView full Avsola profile
CyltezoView full Cyltezo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.